The FDA has approved the first oral medication that combines three type 2 diabetes treatments into one pill: the SGLT2 inhibitor empagliflozin, the DPP-IV inhibitor linagliptin and metformin hydrochloride extended release. This triple combination therapy, called Trijardy XR, is approved to lower blood glucose for adults with type 2 diabetes along with diet and exercise. Read more